Conference Coverage

CBT-I bests acupuncture for treating insomnia among cancer survivors


 

REPORTING FROM ASCO 2018


Insomnia among cancer survivors is both prevalent and problematic, agreed ASCO President Bruce E. Johnson, MD, FASCO.

“The most common way we treat this is pharmacologically, with sleeping pills,” he noted. “This trial shows that two different methods using something other than medications can help people with sleep, and not only do they help people with sleep, but they improve their quality of life.

“We think this information will be helpful for clinicians who end up having to decide, and also, we would use this information to help decide about how the severity of the insomnia is going to influence the treatment,” maintained Dr. Johnson, who is also a professor of medicine at the Dana-Farber Cancer Institute in Boston, and a leader of the center’s lung cancer program.

Study details

The CHOICE trial did not have any restrictions on cancer type or stage; more than a half-dozen types were represented among the 160 patients enrolled, with breast cancer (31%) and prostate cancer (23%) accounting for the largest shares. The majority of patients were white (70%) and had moderate to severe insomnia (79%).

Recommended Reading

Marijuana: Most oncologists are having the conversation
MDedge Hematology and Oncology
Patients with CF at increased risk for GI cancers
MDedge Hematology and Oncology
Intravenous antiemetic combination is well tolerated
MDedge Hematology and Oncology
Breast cancer: More pathogenic variants detected as multiple-gene sequencing takes over
MDedge Hematology and Oncology
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Hematology and Oncology
Upfront NGS testing of metastatic NSCLC saves money, time
MDedge Hematology and Oncology
Palliative care may reduce suicide among lung cancer patients
MDedge Hematology and Oncology
CRC recurrence surveillance studies: No benefit to high-intensity strategy
MDedge Hematology and Oncology
New remote monitoring system lessens symptoms in head and neck cancer
MDedge Hematology and Oncology
FDA advisory panelists reject Buvaya for acute pain
MDedge Hematology and Oncology